Research Category: Oral Presentations

Metabolic syndrome

Fusco J, Wesolowski L, Becker S, Balu R, Fusco G. Metabolic syndrome. Oral presentation. 3rd Annual North American HIV Cohorts Meeting. Nov 2002, Washington D.C;.

Virologic Response to HAART

McKinnon E, Fusco J, John M, Fusco G, Becker S, James I, Mallal S. Virologic Response to HAART. Oral presentation. 3rd  Annual North American HIV Cohorts Meeting. Nov, 2002, Washington D.C

HIV survival: liver function tests independently predict survival

Justice AC, Wagner JH, Fusco GP, Fusco JS, Dieterich DT, Becker SL, McGinnis KA, Conigliaro J, Bonomo R, and Rodriguez-Barradas M. HIV survival: liver function tests independently predict survival. Oral presentation. 1058. XIV International AIDS Conference. July 2002, Barcelona, Spain

The effect of treatment Interruption in patients with virologic failure: results from a multi-cohort collaborative study

Sabin C, Phillips A, Fusco J, Youle M, Gill J, Barbour J, D’Arminio Monforte A, Dauer B, Staszewski S, Braun J, Deeks S, Miller V. The effect of treatment Interruption in patients with virologic failure: results from a multi-cohort collaborative study. Oral presentation. 8th Conference on Retroviruses and Opportunistic Infections. Feb 2001, Chicago, IL

Treatment interruptions

Braun JF, Fusco JS. Treatment interruptions. Oral presentation. 2nd Annual North American HIV Cohorts Meeting, Dec 2000, Washington D.C

Nucleoside reverse transcriptase inhibitor sequencing—prior d4T therapy impairs viral load response to ZDV-containing regimens to a greater extent than ZDV prior to d4T

Becker S, Fusco G, Hansen N, Fusco J, Wilson D, Graham, N, Igboko E. Nucleoside reverse transcriptase inhibitor sequencing—prior d4T therapy impairs viral load response to ZDV-containing regimens to a greater extent than ZDV prior to d4T. Oral presentation. International Workshop on Salvage Therapy for HIV infection, May 1999, Toronto, Canada